<DOC>
	<DOCNO>NCT02078089</DOCNO>
	<brief_summary>This open-label , single arm , Phase Ib dose escalation study Oxcarbazepine morphine patient refractory cancer pain . The primary endpoint evaluate safety toxicity combination Oxcarbazepine plus morphine . The secondary endpoint improve pain control , reduce morphine use improve quality life .</brief_summary>
	<brief_title>Oxcarbazepine Plus Morphine Patients With Refractory Cancer Pain</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<criteria>Written inform consent HIPAA authorization release personal health information . •≥ 18 year old time inform consent Patients histologically confirm diagnosis cancer NOTE : Patients active cancer post treatment allow study . Patients must receive stable increase dos morphine 12 week prior registration protocol therapy . NOTE : Switching patient current pain regimen morphine equivalent least 12 week prior registration protocol therapy require . Requiring great equal 180 mg morphine per day . See Appendix 1 Morphine Conversion Calculator . Inadequately control pain even use morphine ( VAS score &gt; 5 ) See Appendix 8 Rescue pain medication allow may include use NSAIDS Tylenol well morphine IR . ECOG Performance Status 02 Ability swallow tolerate oral tablet . Patients get radiation therapy allow discretion treat physician . Females childbearing potential must negative pregnancy test NOTE : Females consider child bear potential unless surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( &gt; 12 month since last menses ) . NOTE : Females use hormonal contraceptive switch nonhormonal form contraception . The following laboratory value must obtain . Patient aplastic anemia exclude . White blood cell count ( WBC ) ≥ 3.0 K/mm3 Absolute neutrophil count ≥ 1.5 K/mm3 Hemoglobin ( Hgb ) ≥ 9 g/dL Platelets ≥ 75 K/mm3 Creatinine ≤ 1.5 mg/dl Bilirubin ≤ 1.5 x ULN Aspartate aminotransferase ( AST , SGOT ) ≤ 3 x ULN Alanine aminotransferase ( ALT , SGPT ) ≤ 3 x ULN • Active central nervous system ( CNS ) metastasis . Patients neurological symptom undergo head CT scan brain MRI exclude brain metastasis , discretion treat physician . NOTE : Patients prior brain metastasis may consider complete treatment brain metastasis , long require corticosteroid , asymptomatic . • Concurrent use adjuvant medication limit : gabapentin , pregabalin duloxetine etc . NOTE : Patients gabapentin pregabalin consider taper enrol study . Treatment investigational agent within 30 day prior registration protocol therapy . Patient rapidly escalate pain require hospitalization intravenous opioid therapy Concurrent participation clinical trial involve another investigational agent . Concurrent use medication strong CYP3A4 inhibitor within 14 day prior registration protocol therapy Oxcarbazepine strong CYP3A4 inducer . See Appendix 7 . NOTE : Concurrent use CYP3A4 inhibitor may allow discretion treat physician principal investigator . Allergic reaction carbamazepine oxcarbazepine ( HLAB1502 ) Allergy contraindication morphine sulphate Opiateinduced uncontrolled constipation bowel obstruction Patient live alone . Female pregnant breastfeeding Patient diagnosis epilepsy and/or currently take antiepileptic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Refractory cancer pain</keyword>
</DOC>